RECRUITING

Predictors of Aspirin Failure in Preeclampsia Prevention

Description

Hypertensive disorders of pregnancy (including preeclampsia) are among the leading causes of pregnancy complications and maternal deaths worldwide. They also increase the risks to the babies. Numerous interventions have been suggested in order to reduce the rate of preeclampsia. Low-dose aspirin is the most beneficial prophylactic approach in this regard. Nevertheless, aspirin failure is not uncommon. The genetic, laboratory, and clinical factors associated with low-dose aspirin failure in the prevention of preeclampsia are largely unknown. The presence of a genetic variant in PAR4 receptor expressed on platelets, is associated with increased platelet function and possibly with aspirin failure.

Conditions

Preeclampsia
Talk to us

Related Conditions:

Preeclampsia

Study Overview

On this page

Study Details

Study overview

Hypertensive disorders of pregnancy (including preeclampsia) are among the leading causes of pregnancy complications and maternal deaths worldwide. They also increase the risks to the babies. Numerous interventions have been suggested in order to reduce the rate of preeclampsia. Low-dose aspirin is the most beneficial prophylactic approach in this regard. Nevertheless, aspirin failure is not uncommon. The genetic, laboratory, and clinical factors associated with low-dose aspirin failure in the prevention of preeclampsia are largely unknown. The presence of a genetic variant in PAR4 receptor expressed on platelets, is associated with increased platelet function and possibly with aspirin failure.

Genetic, Laboratory and Clinical Factors Associated With Low-dose Aspirin Failure in the Prevention of Preeclampsia- An Exploratory Protocol

Predictors of Aspirin Failure in Preeclampsia Prevention

Condition
Preeclampsia
Intervention / Treatment

-

Contacts and Locations

New York

Rockefeller University, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Women aged 18-45 years with prior history of preeclampsia who received low dose aspirin in their subsequent gestation and either did or did not have a recurrence of preeclampsia.
  • 2. Aspirin was given in their subsequent pregnancy in a 81 mg dose prior to 16 weeks of gestation, and was taken with a self-reported compliance rate of at least 80%
  • 3. Subsequent pregnancy lasted beyond 20 weeks of gestation
  • 4. Willingness to abstain from non-prescription non-steroidal anti-inflammatory drugs (NSAIDs), which are known to interfere with platelet function assays, for one week prior to platelet function analyses.
  • 5. Healthy controls recruited for SNP assay optimization:
  • 1. Age \<18 years or \>45 years
  • 2. Any clinically significant adverse reaction to aspirin on prior exposure
  • 3. Known bleeding disorder based on personal or family history
  • 4. History of kidney or liver impairment
  • 5. Current pregnancy
  • 6. Current use of antithrombotic agents (e.g., aspirin, clopidogrel, warfarin, direct acting oral anticoagulants).
  • 7. Chronic hypertension (systolic blood pressure \>140 mmHG or diastolic pressure \>90 mmHG, or use of antihypertensive drugs or diagnosis made by clinician)
  • 8. Diabetes mellitus
  • 9. Current known malignancy
  • 10. History of hemorrhagic stroke
  • 11. Participants may be excluded at the discretion of the investigator for medical, psychological or other reasons
  • 12. Rockefeller students, and Rockefeller employees in the Coller lab, are excluded from participation.
  • 13. Healthy controls:

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Rockefeller University,

Amihai Rottenstreich, MD, PRINCIPAL_INVESTIGATOR, Rockefeller University

Study Record Dates

2025-11-01